The Technical Analyst
AgeX Therapeutics Inc [AGE]
Exchange: AMEX Sector: Healthcare Industry: Biotechnology
AgeX Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-11.90% $11.10
America/New_York / 26 mar 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 27.76 mill |
| EPS: | -482.53 |
| P/E: | -0.0200 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 2.50 mill |
| Avg Daily Volume: | 0.0040 mill |
| RATING 2024-03-26 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0200 | sector: PE -4.07 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0200 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-3.97 (-135.79%) $-15.07 |
| Date: 2024-04-01 |
| Expected Trading Range (DAY) |
|---|
|
$ 10.05 - 12.15 ( +/- 9.48%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-08 | Mintz Steven | Sell | 0 | Common Stock, $0.0001 par value |
| 2024-01-08 | Mintz Steven | Sell | 63 756 | Option to Purchase Common Stock |
| 2023-08-09 | Renondin Jean-christophe | Sell | 25 821 | Option to Purchase Common Stock |
| 2023-04-25 | Juvenescence Ltd | Buy | 756 429 | Warrant to Purchase Common Stock |
| 2023-03-14 | Juvenescence Ltd | Sell | 16 447 500 | Common Stock |
| INSIDER POWER |
|---|
| -62.48 |
| Last 97 transactions |
| Buy: 22 648 571 | Sell: 17 037 050 |
Forecast:
16:00 - $11.10
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $11.10
Forecast 2: 16:00 - $11.10
Forecast 3: 16:00 - $11.10
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $11.10 (-11.90% ) |
| Volume | 0.0037 mill |
| Avg. Vol. | 0.0040 mill |
| % of Avg. Vol | 92.49 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AGE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AGE
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
Latest Press Releases
2024-03-26 17:04:00 - Press Release
Serina Therapeutics Announces Completion Of Merger With Agex Therapeutics
Huntsville, ala., march 26, 2024 (globe newswire) -- serina therapeutics (nyse american: ser), a clinical-stage biotechnology company developing a pipeline of therapies for the treatment of parkinson's disease and other neurological diseases, today announced the closing of its previously announced merger with a wholly-owned subsidiary of agex therapeutics, inc. the combined company will operate under the name serina therapeutics and will trade on the nyse american market under the ticker symbol “ser” effective with the open of business on wednesday, march 27, 2024. the new cusip number for the combined company following the merger is 81751a108.
2024-03-22 17:27:00 - Press Release
Agex Therapeutics Reports Fourth Quarter And Annual 2023 Financial Results
Alameda, calif., march 22, 2024 (globe newswire) -- agex therapeutics, inc. (“agex”; nyse american: age), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended december 31, 2023 and recent highlights.
2024-02-27 15:19:00 - Press Release
Agex Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Agex Therapeutics, Inc. - Age
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of agex therapeutics, inc. (nyse: age) with serina therapeutics, inc. pursuant to which agex shareholders are expected to own approximately 25% of the newly combined company. ksf is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the company.
2023-11-14 16:05:00 - Press Release
Agex Therapeutics Reports Third Quarter 2023 Financial Results
Alameda, calif.--(business wire)--agex therapeutics, inc. (“agex”; nyse american: age), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended september 30, 2023. third quarter and recent highlights $36 million of indebtedness converted into preferred stock signed agreement and plan of merger and reorganization to acquire serina therapeutics, inc. obtained $4.4 million addition to line.
2023-09-05 18:52:00 - Press Release
Agex Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Agex Therapeutics, Inc. - Age
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of agex therapeutics, inc. (nyse: age) with serina therapeutics, inc. pursuant to which agex shareholders are expected to own approximately 25% of the newly combined company. ksf is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the company.
Latest News
2023-08-30 10:22:59 - Proactive Investors
Serina Therapeutics merger promises to reboot ‘human longevity' firm AgeX
Privately-owned Serina Therapeutics Inc is being merged into AgeX Therapeutics (NYSE:AGE) in a move that will reboot the Nasdaq ‘human longevity' stock, into an immunology and gene therapy firm seeking a treatment of Parkinson's disease. Holders of Serina, a specialist in ‘small molecule' central nervous system drug discovery, will own 75% of the combined company's equity as a result of the ‘reverse merger' transaction.
2021-08-13 16:05:00 - Business Wire
AgeX Therapeutics Reports Second Quarter 2021 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2021. Liquidity and Capital Resources As of August 13, 2021, AgeX has $2.0 million of funds remaining for borrowings under two credit facilities from Juvenescence Limited (“Juvenescence”). In addition, AgeX may sell up to $12.1 million of its common sto
2021-07-23 16:15:00 - Business Wire
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
ALAMEDA, Calif. & PITTSBURGH--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (“LyGenesis”), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they have discontinued negotiations for a merger agreement. The board of directors of AgeX and the board of directors of LyGenesis each determined that it was
2021-04-14 14:47:29 - Seeking Alpha
AgeX Therapeutics: New LyGenesis Merger May Unlock Much-Needed Value
AgeX Therapeutics, Inc. is a longevity-focused biotechnology company aiming to develop novel therapeutics for human aging and degenerative diseases.
2021-03-12 08:00:00 - Business Wire
AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today the online publication of data relating to regeneration, aging, and cancer in bioRxiv. The paper titled “Differential Expression of α, β, and γ Protocadherin Isoforms During Differentiation, Aging, and Cancer” presents for the first time data relating to mechanisms cells may use in the process of regeneration. T
2021-03-10 08:00:00 - Business Wire
AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX's Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today a research collaboration with The Ohio State University using AgeX's brown adipocyte tissue (BAT) cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health including glucose metabolism, and cardiac function. The research wi
2020-12-22 15:08:00 - Business Wire
AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to be held at 10:00 a.m. Pacific Standard Time on Monday, December 28, 2020 will be permitted only through online participation. The County of Alameda, California, where AgeX's offices are located and where AgeX had planned to hold the Annual Meeting, has iss
2020-11-27 16:13:02 - Insider Monkey
Where Do Hedge Funds Stand On AgeX Therapeutics, Inc. (AGE)?
Is AgeX Therapeutics, Inc. (NYSE:AGE) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. The top picks of these firms have historically outperformed the market when we account for known risk factors, making them very valuable investment ideas.
2020-10-09 00:00:00 - benzinga
Mid-Day Market Update: Gold Gains 2%; ShiftPixy Shares Plunge
Midway through trading Friday, the Dow traded up 0.44% to 28549.53 while the NASDAQ rose 0.99% to 11534.04. The S&P also rose, gaining 0.59% to 3467.29.
The U.S. has the...
2020-10-08 00:00:00 - benzinga
Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Consumer Portfolio Services Shares Spike Higher
Toward the end of trading Thursday, the Dow traded up 0.38% to 28411.68 while the NASDAQ rose 0.35% to 11404.34. The S&P also rose, gaining 0.69% to 3442.96.
The U.S. has the...